Bapineuzumab: Anti-β-amyloid monoclonal antibodies for the treatment of Alzheimers disease

Francesco Panza, Vincenza Frisardi, Bruno P. Imbimbo, Grazia Donofrio, Giuseppe Pietrarossa, Davide Seripa, Alberto Pilotto, Vincenzo Solfrizzi

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

In the last decade, new therapeutic approaches targeting b-amyloid (Aβ) have been discovered and developed with the hope of modifying the natural history of Alzheimer's disease (AD). The most revolutionary of these approaches consists in the removal of brain Aβ via anti-Aβ antibodies. After an active vaccine (AN1792) was discontinued in 2002 due to occurrence of meningoencephalitis in approximately 6% of patients, several other second-generation active Aβ vaccines and passive Aβ immunotherapies have been developed and are under clinical investigation with the aim of accelerating Aβ clearance from the brain of AD patients. The most advanced of these immunological approaches is bapineuzumab, which is composed of humanized anti-Aβ monoclonal antibodies that has been tested in two Phase II trials. Bapineuzumab has been shown to reduce Aβ burden in the brain of AD patients. However, its preliminary cognitive efficacy appears uncertain, particularly in ApoE ε4 carriers, and vasogenic edema may limit its clinical use. The results of four ongoing large Phase III trials on bapineuzumab will provide answers regarding whether passive anti-Aβ immunization is able to alter the course of this devastating disease.

Original languageEnglish
Pages (from-to)767-782
Number of pages16
JournalImmunotherapy
Volume2
Issue number6
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Amyloid
Alzheimer Disease
Monoclonal Antibodies
Brain Diseases
Vaccines
Meningoencephalitis
Passive Immunization
Apolipoproteins E
Anti-Idiotypic Antibodies
Immunization
Edema
Therapeutics
Brain
bapineuzumab

Keywords

  • β-amyloid
  • active immunotherapy
  • Alzheimer's disease
  • bapineuzumab
  • passive immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Bapineuzumab : Anti-β-amyloid monoclonal antibodies for the treatment of Alzheimers disease. / Panza, Francesco; Frisardi, Vincenza; Imbimbo, Bruno P.; Donofrio, Grazia; Pietrarossa, Giuseppe; Seripa, Davide; Pilotto, Alberto; Solfrizzi, Vincenzo.

In: Immunotherapy, Vol. 2, No. 6, 11.2010, p. 767-782.

Research output: Contribution to journalArticle

Panza, F, Frisardi, V, Imbimbo, BP, Donofrio, G, Pietrarossa, G, Seripa, D, Pilotto, A & Solfrizzi, V 2010, 'Bapineuzumab: Anti-β-amyloid monoclonal antibodies for the treatment of Alzheimers disease', Immunotherapy, vol. 2, no. 6, pp. 767-782. https://doi.org/10.2217/imt.10.80
Panza, Francesco ; Frisardi, Vincenza ; Imbimbo, Bruno P. ; Donofrio, Grazia ; Pietrarossa, Giuseppe ; Seripa, Davide ; Pilotto, Alberto ; Solfrizzi, Vincenzo. / Bapineuzumab : Anti-β-amyloid monoclonal antibodies for the treatment of Alzheimers disease. In: Immunotherapy. 2010 ; Vol. 2, No. 6. pp. 767-782.
@article{813e0e133fe94dc19a0c96eba8d46865,
title = "Bapineuzumab: Anti-β-amyloid monoclonal antibodies for the treatment of Alzheimers disease",
abstract = "In the last decade, new therapeutic approaches targeting b-amyloid (Aβ) have been discovered and developed with the hope of modifying the natural history of Alzheimer's disease (AD). The most revolutionary of these approaches consists in the removal of brain Aβ via anti-Aβ antibodies. After an active vaccine (AN1792) was discontinued in 2002 due to occurrence of meningoencephalitis in approximately 6{\%} of patients, several other second-generation active Aβ vaccines and passive Aβ immunotherapies have been developed and are under clinical investigation with the aim of accelerating Aβ clearance from the brain of AD patients. The most advanced of these immunological approaches is bapineuzumab, which is composed of humanized anti-Aβ monoclonal antibodies that has been tested in two Phase II trials. Bapineuzumab has been shown to reduce Aβ burden in the brain of AD patients. However, its preliminary cognitive efficacy appears uncertain, particularly in ApoE ε4 carriers, and vasogenic edema may limit its clinical use. The results of four ongoing large Phase III trials on bapineuzumab will provide answers regarding whether passive anti-Aβ immunization is able to alter the course of this devastating disease.",
keywords = "β-amyloid, active immunotherapy, Alzheimer's disease, bapineuzumab, passive immunotherapy",
author = "Francesco Panza and Vincenza Frisardi and Imbimbo, {Bruno P.} and Grazia Donofrio and Giuseppe Pietrarossa and Davide Seripa and Alberto Pilotto and Vincenzo Solfrizzi",
year = "2010",
month = "11",
doi = "10.2217/imt.10.80",
language = "English",
volume = "2",
pages = "767--782",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Bapineuzumab

T2 - Anti-β-amyloid monoclonal antibodies for the treatment of Alzheimers disease

AU - Panza, Francesco

AU - Frisardi, Vincenza

AU - Imbimbo, Bruno P.

AU - Donofrio, Grazia

AU - Pietrarossa, Giuseppe

AU - Seripa, Davide

AU - Pilotto, Alberto

AU - Solfrizzi, Vincenzo

PY - 2010/11

Y1 - 2010/11

N2 - In the last decade, new therapeutic approaches targeting b-amyloid (Aβ) have been discovered and developed with the hope of modifying the natural history of Alzheimer's disease (AD). The most revolutionary of these approaches consists in the removal of brain Aβ via anti-Aβ antibodies. After an active vaccine (AN1792) was discontinued in 2002 due to occurrence of meningoencephalitis in approximately 6% of patients, several other second-generation active Aβ vaccines and passive Aβ immunotherapies have been developed and are under clinical investigation with the aim of accelerating Aβ clearance from the brain of AD patients. The most advanced of these immunological approaches is bapineuzumab, which is composed of humanized anti-Aβ monoclonal antibodies that has been tested in two Phase II trials. Bapineuzumab has been shown to reduce Aβ burden in the brain of AD patients. However, its preliminary cognitive efficacy appears uncertain, particularly in ApoE ε4 carriers, and vasogenic edema may limit its clinical use. The results of four ongoing large Phase III trials on bapineuzumab will provide answers regarding whether passive anti-Aβ immunization is able to alter the course of this devastating disease.

AB - In the last decade, new therapeutic approaches targeting b-amyloid (Aβ) have been discovered and developed with the hope of modifying the natural history of Alzheimer's disease (AD). The most revolutionary of these approaches consists in the removal of brain Aβ via anti-Aβ antibodies. After an active vaccine (AN1792) was discontinued in 2002 due to occurrence of meningoencephalitis in approximately 6% of patients, several other second-generation active Aβ vaccines and passive Aβ immunotherapies have been developed and are under clinical investigation with the aim of accelerating Aβ clearance from the brain of AD patients. The most advanced of these immunological approaches is bapineuzumab, which is composed of humanized anti-Aβ monoclonal antibodies that has been tested in two Phase II trials. Bapineuzumab has been shown to reduce Aβ burden in the brain of AD patients. However, its preliminary cognitive efficacy appears uncertain, particularly in ApoE ε4 carriers, and vasogenic edema may limit its clinical use. The results of four ongoing large Phase III trials on bapineuzumab will provide answers regarding whether passive anti-Aβ immunization is able to alter the course of this devastating disease.

KW - β-amyloid

KW - active immunotherapy

KW - Alzheimer's disease

KW - bapineuzumab

KW - passive immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=78649526412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649526412&partnerID=8YFLogxK

U2 - 10.2217/imt.10.80

DO - 10.2217/imt.10.80

M3 - Article

C2 - 21091109

AN - SCOPUS:78649526412

VL - 2

SP - 767

EP - 782

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 6

ER -